Showing posts with label Gastrointestinal. Show all posts
Showing posts with label Gastrointestinal. Show all posts
1 comments Monday, May 4, 2009

Family members of children diagnosed with non-alcoholic fatty liver disease (NAFLD) should be considered at high risk for the disease and tested for it as part of a routine medical examination, even if they don't show symptoms, according to a recent study by researchers at the University of California, San Diego School of Medicine. The results will be published in the May edition of the journal Gastroenterology.

"As we suspected, NAFLD is not simply about weight, but rather is highly familial and likely genetic," said principal investigator Jeffrey B. Schwimmer, MD, associate professor of pediatrics and director of the Fatty Liver Clinic at Rady Children's Hospital San Diego.

NAFLD is now the most common cause of chronic liver disease is the United States. NAFLD refers to a spectrum of liver disease that begins with liver cells abnormally storing fat, in the absence of chronic alcohol use. NAFLD can be mild in some people, but in a subset with the progressive form (steatoehepatitis or NASH) there is risk for cirrhosis, liver cancer, and liver-related death. Based upon clinical observation, doctors have speculated that NAFLD may be a genetic disease, but lacked scientific support for this idea.

The current study takes a major step in building the case that NAFLD is a genetic disease. The research team studied 44 children with and without NAFLD and 152 family members of these children. In order to determine the amount of fat in the liver of each participant they used a state of the art magnetic resonance imaging (MRI) technique developed at UC San Diego. The researchers also performed tests to exclude other factors that can cause a fatty liver other than NAFLD.

The researchers found that whether or not a given person had NAFLD was highly heritable whether or not the child had NAFLD was a major determinant of the amount of liver fat present in the other family members. In the families of overweight children without NAFLD, siblings and parents had NAFLD at rates that were similar to the background population's rates of NAFLD. The rates of NAFLD were much higher in family members of children with NAFLD; it was present in 59% of siblings and 78% of parents. In most cases the person did not know that they had the disease. In a few cases the disease was already very advanced even in the absence of symptoms.

"Being overweight is a risk factor for NAFLD, but this is strongly modified by the underlying genetics," said Schwimmer. "So some people can have high body weights without any storage of fat in the liver. But in susceptible families, there's an additive effect. Regardless of weight, they are more likely to have NAFLD for genetic reasons. In addition, the more overweight such a person is, the more likely they are to have dangerous amounts of fat in their liver."

The researchers recommend that if one family member tests positive for NAFLD, other family members should talk to their doctors immediately. Early detection could catch NAFLD at a stage where the disease is reversible and further complications may be prevented before cirrhosis sets in.

Schwimmer hopes that further studies will disclose specific genetic and environmental factors that influence the development and severity of the disease, which could provide helpful information to a wide array of health care practitioners.

"Understanding that this disease runs in families may help an entire family create a healthy lifestyle with regular exercise and a heart-healthy liver healthy diet," said Schwimmer.

After participating in the study, Susanne Hernandez and her family have already changed the way they live. Like so many children with NAFLD, her 12 year-old son was identified on accident. Because of his asthma, he was scheduled to participate in a clinical trial for asthma management, but first had screening blood tests including an ALT. This test led to evaluation by a gastroenterologist and the surprising finding of severe liver disease. A quick web search led to the family becoming part of Schwimmer's research. Debbie, her son and her husband are now being treated for liver disease. Luckily, their daughter is not affected.

"This study made us more aware that we have to make changes," explained Hernandez. "After getting proper attention, my son is much more alert, and we pay attention to his fatigue, keeping him hydrated and we're on a good nutrition routine."

Previous studies by UC San Diego investigators showed that:

-- NAFLD is present in 9.6 percent of the children and adolescents living in San Diego County

-- Nearly all children with NAFLD are insulin resistant

In children, NAFLD is a major risk factor for and cardiovascular disease.

Additional contributors include Manuel Celedon, Joel Lavine, MD, PhD, UCSD department of pediatrics; Takeshi Yokoo, MD, Masoud Shiehmorteza, Michael S. Middleton, MD, PhD, and Claude B. Sirlin, M.D., and Alyssa Chavez, UCSD department of radiology; Rany Salem, PhD, Nzali Campbell, PhD and Nicholas Schork, PhD, Scripps Health and The Scripps Research Institute.

This work was funded by grants from the National Institutes of Health, the National Institute of Diabetes and Digestive and Kidney Diseases, the National Center of Minority Health and Health Disparities and the National Center for Research Resources.

Source: University of California, San Diego

0 comments

It is well known that non-cardiac chest pain is closely related to gastroesophageal reflux diseases (GERD). Chest pain of esophageal origin can be difficult to distinguish from that caused by cardiac ischemia because the distal esophagus and the heart share a common afferent vagal supply, and GERD can cause episodes of non-cardiac chest pain that resemble ischemic cardiac pain.

A research team led by Dr. Yoshihisa Urita from Toho University School of Medicine investigated the association between gastroesophageal reflux diseases (GERD) and coronary heart diseases. Their study was published on April 14, 2009 in the World Journal of Gastroenterology.

One thousand nine hundred and seventy consecutive patients were enrolled in this study. All of the patients who first attend their hospital were asked to respond to the F-scale questionnaire regardless of their chief complaints. All patients had a careful history taken, and resting echocardiography (ECG) was performed by physicians if the diagnostic necessity arose. Patients with ECG signs of coronary artery ischemia were defined as ST segment depression based on the Minnesota code.

Among 712 patients (36%) with GERD, ECG was performed in 171 (24%), and ischemic changes were detected in eight (5%). Four (50%) of these patients with abnormal findings upon ECG had no chest symptoms such as chest pain, chest oppression, or palpitations. These patients (0.6%; 4/712) were thought to have non-GERD heartburn, which may be related to ischemic heart disease. Of the 281 patients who underwent ECG and did not have GERD symptoms, 20 (7%) had abnormal findings upon ECG. In patients with GERD symptoms and ECG signs of coronary artery ischemia, the prevalence of linked angina was considered to be 0.4% (8/1970 patients).

The study results suggest that an extra-esophageal condition causes GERD symptoms and that angina may be misclassified as GERD. Since patients with GERD have an increased risk of angina pectoris in the year after GERD diagnosis, physicians have to be concerned about missing clinically important CAD while evaluating patients for GERD symptoms.

Reference: Kato H, Ishii T, Akimoto T, Urita Y, Sugimoto M. Prevalence of linked angina and gastroesophageal reflux disease in general practice. World J Gastroenterol 2009; 15(14): 1764-1768. http://www.wjgnet.com/1007-9327/15/1764.asp

Correspondence to: Dr. Yoshihisa Urita, Department of General Medicine and Emergency Care, Toho University School of Medicine, Omori Hospital, 6-11-1, Omori-Nishi, Ota-Ku, Tokyo

Source:
Lai-Fu Li
World Journal of Gastroenterology

3 comments Monday, November 24, 2008

caAccording to the American Cancer Society (ACS), more than 16,000 new esophageal cancer cases are diagnosed each year in the U.S. Unfortunately the survival rate in these cases is only 10 percent. This alarming statistic is due largely to the fact that by the time the majority of cases are diagnosed, the cancerous tumors have grown to the point of inoperability. Raising patient awareness about potential conditions that, if left untreated, could progress into esophageal cancer, will encourage patients to seek the appropriate care through their physician.

Many people are aware that tobacco use increases the risk of developing esophageal cancer; however, there are several other common contributing risk factors including:

- Excessive alcohol consumption;
- Obesity;
- Lye ingestion; and,
- Gastroesophageal reflux disease (GERD), also known as acid reflux or heartburn.

A recent ACS Gallup poll revealed that 44 percent of adults in the U.S. have heartburn at least once per month and that approximately 30 percent of esophageal cancer cases can be linked to GERD. GERD is a condition in which acid (with some pepsin and bile) splashes up from the stomach into the esophagus. These three fluids are potentially dangerous to the sensitive esophageal tissue, as they can inflame and damage the lining of the esophagus, a condition known as esophagitis.

If GERD becomes a chronic condition, it can develop into Barrett's esophagus, a precursor to esophageal cancer. Barrett's esophagus is a condition in which the color and composition of the cells lining the lower esophagus change due to repeated exposure to stomach acid. Only a small percentage of people with GERD develop Barrett's esophagus, but once it is diagnosed, patients should be sure to meet with their physician regularly as they are at a greater risk of developing esophageal cancer.

Symptoms of advanced GERD or the presence of Barrett's esophagus include:

- Frequent heartburn. A burning-type pain in the lower part of the mid-chest, behind the breast bone, and in the mid-abdomen.
- Difficulty swallowing. Often, a narrowing of the esophagus (esophageal stricture) leads to trouble swallowing or dysphagia.
- Bleeding. A person may vomit red blood or blood that looks like coffee grounds, or your stools may be black, tarry or bloody.
- Weight loss and loss of appetite.

According to the ACS, prevention of Barrett's esophagus can begin with controlling GERD by making some simple lifestyle changes, such as:

- Losing weight. Obesity increases abdominal pressure, which can then push stomach contents up into the esophagus;
- Eating a diet full of fruits and vegetables, eating smaller and more frequent meals and not eating two to three hours prior to bedtime;
- Smoking cessation, as nicotine relaxes the esophageal sphincter and smoking also stimulates the production of stomach acid;
- Discontinuing the consumption of alcohol.

People with severe GERD and Barrett's esophagus often require aggressive treatment and prevention methods including medications, other nonsurgical medical procedures such as endoscopic therapies, or even laparoscopic and open surgeries. Often times, swallowing difficulty (known as dysphagia) and other symptoms can be treated if identified early.

However, due to the aggressive nature of the disease, the majority of patients who have esophageal cancer are not surgical candidates. In these situations, the primary focus becomes palliative care - providing comfort measures to help maintain quality of life. This includes treating the dysphagia and restoring the patient's ability to swallow food and drink liquids by opening the stricture within the esophagus.

To open the barriers caused by tumor in-growth physicians use an esophageal metal stent. Prior to the stent placement the patient may require dilation of the stricture to allow room for the stent to be positioned, thereby expanding the lumen of the esophagus. Traditionally, the placement of the stent can be a painful process for the patient, yet new technologies are making this procedure easier on the patient and physician.

New, innovative delivery systems enable accurate deployment and recapturability of the stent. This reduces the stent from moving or migrating into the stomach and thus the need for repeat procedures to replace or reposition the stent, one of the more common complications in traditional esophageal stenting.

Raising awareness about the primary pre-cursors to esophageal cancer - GERD and Barrett's esophagus - will encourage patients with these conditions to consult their physicians for the necessary screenings and treatment options. However, when palliative care becomes the primary option for patients with esophageal cancer, recent advancements in medical device technologies enable physicians to more easily implant an esophageal stent and in turn improve patients' quality of life.

Medicalnews

0 comments Monday, August 11, 2008

People who have gastrointestinal (GI) bleeding after a stroke are more likely to die or become severely disabled than stroke sufferers with no GI bleeding, according to a study published in the August 6, 2008, online issue of Neurology®, the medical journal of the American Academy of Neurology.

"This is an important finding since there are effective medications to reduce gastric acid that can lead to upper gastrointestinal bleeding," said study author Martin O'Donnell, MB, of McMaster University in Hamilton, Ontario. "More research will be needed to determine whether this is a viable strategy to improve outcomes after stroke in high-risk patients."

The study involved 6,853 people who had ischemic strokes. The most common type of stroke, ischemic strokes occur when blood flow to the brain is reduced or blocked. Of those, 829 people died during their hospital stay and 1,374 had died within six months after the stroke.

A total of 100 people, or 1.5 percent, had gastrointestinal bleeding, or bleeding in the stomach or intestines, while they were in the hospital from the stroke. In more than half of the cases, the GI bleeding occurred in people who had mild to moderate strokes.

The people with GI bleeding were more than three times more likely to die during their hospital stay or be severely dependent on others for their care at the time they left the hospital than people who did not have GI bleeding. A total of 81 percent of those with GI bleeding died in the hospital or were severely dependent, compared to 41 percent of those without GI bleeding.

Those with GI bleeding were also 1.5 times more likely to have died within six months after the stroke than those without GI bleeding. Of those with GI bleeding, 46 percent had died within six months, compared to 20 percent of those without GI bleeding. This relationship remained even after researchers adjusted for other factors, including other conditions such as pneumonia and heart attack.

The study was supported by the Canadian Stroke Network, the Ontario Ministry of Health and Long-term Care, the Canadian Institutes of Health Research, the Institute for Clinical Evaluative Sciences and the University Health Network Women's Health Program in Toronto.

The American Academy of Neurology, an association of more than 21,000 neurologists and neuroscience professionals, is dedicated to improving patient care through education and research. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as stroke, Alzheimer's disease, epilepsy, Parkinson's disease, and multiple sclerosis.

For more information about the American Academy of Neurology, visit http://www.aan.com.

0 comments Wednesday, April 30, 2008

Medicalnews

A new study, published in the journal "Digestion", determined the diagnostic and therapeutic response of the Reflux Disease Questionnaire (RDQ) using the symptom association probability as reference. The symptom association probability objectively determines with a Fisher exact test whether symptoms are due to reflux events taking all symptom episodes and reflux events into account. In addition, the RDQ's construct validity and its relationship to quality of life were ascertained.

Seventy-four patients with gastro-oesophageal reflux disease (GORD) symptoms (age 51 years (22-78); male 62%) derived from primary care completed the RDQ, Gastrointestinal Rating Scale and Quality of Life in Reflux and Dyspepsia (QOLRAD) questionnaires before and after a two-week course of esomeprazole, a proton pump inhibitor (40 mg daily). The symptom association probability was determined by a 24-hour pH recording before proton pump inhibitor treatment. The diagnostic abilities of the RDQ (total and 4 dimensions scores) were assessed with the area under the curve of a receiver operating curve. RDQ scores before and after proton pump inhibitor treatment were compared with Wilcoxon tests. Multiple linear regressions assessed the RDQ's construct validity (Gastrointestinal Rating Scale) and relationship to quality of life (QOLRAD).

The areas under the curve were low for all RDQ dimensions (<0.6). In patients positive for symptom association probability all RDQ dimensions improved (p < 0.0001) while the scores of those negative for symptom association probability did not (heartburn p < 0.01; GORD and total score p < 0.05; regurgitation and dyspepsia not significant). The RDQ was related to the total and reflux dimensions of the Gastrointestinal Rating Scale, while the food and drink quality of life dimension was linearly associated with the RDQ.

Therefore, the RDQ is a valid and reliable questionnaire with excellent construct validity and a good relationship to quality of life. The diagnostic value of the RDQ in primary care is limited, but combination with an additional proton pump inhibitor treatment course might improve the RDQ's ability to discriminate GORD patients according to their symptom association probability outcome.

1 comments Monday, April 28, 2008


Bland J
Journal of Alterative Medicine, 1985


Jeffrey Bland, Ph.D., formerly of the Linus Pauling Institute, reported using a concentrate of Aloe vera to treat gastrointestinal problems. The objectives of Dr. Bland’s study were “to evaluate the effect of oral Aloe vera juice supplementation of gastric pH, stool specific gravity, protein digestion/absorption, and stool microbiology” and found that it could be used in “the treatment of inflammatory bowel disorders.”

In his patient application studies of ten healthy subjects (five women and five men), Dr. Bland first found that the Aloe vera juice provided caused his subjects no covert or overt adverse effects and was in general “well tolerated” by all ten people in the study group. In his study of five women and five men, Dr. Bland was careful to note that: “...with the taking of two-ounce increments [of the Aloe vera juice] three times daily for seven days no patient among the... (five men, five women) complained of diarrhea... four of the subjects reported improved bowel regularity with greater gastrointestinal comfort after eating... three indicated an enhancement of energy and a greater sense of well being...”

Additionally, he reported that: “The function of Aloe vera juice in promoting proper gastrointestinal function based upon the information from this preliminary study may be to regulate gastrointestinal pH while improving gastrointestinal motility, increasing stool specific gravity and reducing the populations of certain fecal micro-organisms, including yeast [Candida albicans]. This could have significant advantages to some individuals by promoting proper dietary protein digestion and absorption and reducing bowel putrefactive processes in the colon.”